Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Sagimet Biosciences Inc.NASDAQ: SGMT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $11.71M fell 41.0% year over year, behind the -25.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -41.0% toward the trailing-twelve-month pace of -25.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 56.89M USD
- Year-over-year change
- +4.5%
- 4-year CAGR
- +24.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 56.89M | +4.5% |
| FY2024 | 2024-12-31 | 54.45M | +66.3% |
| FY2023 | 2023-12-31 | 32.74M | +5.4% |
| FY2022 | 2022-12-31 | 31.06M | +30.9% |
| FY2021 | 2021-12-31 | 23.72M | — |
Operating Expenses vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 operating expenses of $48.74M is the lowest of the 11 companies compared; the peer median is $91.42M.
- Its year-over-year change of -25.7% is the 9th highest of 11, against a peer median of -0.6%.
- Over three fiscal years its annual growth of +22.4% compares with a peer median of +16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $149.1M | +7.6% | +38.4% | — | |
| LTM Mar 2026 | $144.1M | -14.3% | +22.2% | 2511.3% | |
| LTM Mar 2026 | $130.57M | -39.9% | -10.4% | 287.9% | |
| LTM Mar 2026 | $98.8M | -9.8% | +5.9% | 4900.7% | |
| LTM Mar 2026 | $95.79M | +126.8% | +68.5% | 262.5% | |
| LTM Mar 2026 | $87.05M | -28.0% | -7.0% | 308.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $81.49M | +23.4% | +40.4% | — |
| LTM Mar 2026 | $68.52M | +100.9% | +50.0% | 96.4% | |
| LTM Mar 2026 | $58.43M | -8.8% | +4.2% | — | |
| LTM Mar 2026 | $52.34M | +13.8% | +10.2% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $48.74M | -25.7% | +22.4% | — |
| Peer median (excluding SGMT) | $91.42M | -0.6% | +16.2% | 298.2% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.